Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer:Results from the Dutch Castration-resistant Prostate Cancer Registry

Background: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2). Objective: To establish treatment duration and prostate-specific antigen (PSA) response of ART2 in real-world mCRPC patients treated with or without other life-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) between ART1 and ART2. Design, Setting, and participants: Castration-resistant prostate cancer patients,... Mehr ...

Volltext
Verfasser: Kuppen, Malou C. P.
Westgeest, Hans M.
van den Eertwegh, Alphonsus J. M.
van Moorselaar, Reindert J. A.
van Oort, Inge M.
Coenen, Juleon L. L. M.
van den Bergh, A. C. M. Fons
Mehra, Niven
Somford, Diederik M.
Bergman, Andre M.
Huinink, Daan Ten Bokkel
Fossion, Laurent
Geenen, Maud M.
Hendriks, Mathijs P.
van de Luijtgaarden, Addy C. M.
Polee, Marco B.
Weijl, Nir
van de Wouw, Agnes J.
de Wit, Ronald
Uyl-de Groot, Carin A.
Gerritsen, Winald R.
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Kuppen , M C P , Westgeest , H M , van den Eertwegh , A J M , van Moorselaar , R J A , van Oort , I M , Coenen , J L L M , van den Bergh , A C M F , Mehra , N , Somford , D M , Bergman , A M , Huinink , D T B , Fossion , L , Geenen , M M , Hendriks , M P , van de Luijtgaarden , A C M , Polee , M B , Weijl , N , van de Wouw , A J , de Wit , R , Uyl-de Groot , C A & Gerritsen , W R 2021 , ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ' , European urology oncology , vol. 4 , no. 4 , pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
Schlagwörter: Castration-resistant prostate cancer / Androgen-receptor targeting agents / Abiraterone acetate / Enzalutamide / Real-world outcomes / Cross resistance / Sequencing / ANTITUMOR-ACTIVITY / INCREASED SURVIVAL / CLINICAL-OUTCOMES / DOCETAXEL / TRIALS / TIME
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26670636
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/41b16b5e-d8f6-46e7-904f-77d48f068028